Veracyte reports Phase 3 STAMPEDE trial finding published in Cell

Veracyte (VCYT) and University College London announced that data published online in Cell show that the Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with the chemotherapy docetaxel and which are not likely to benefit and can therefore avoid unnecessary toxicity. “The findings-from the randomized, prospective, Phase 3 STAMPEDE trial-are the first to be published showing that a gene expression test can help clinicians better personalize chemotherapy decisions for patients with metastatic prostate cancer,” the company stated. “The recent introduction of the Decipher test for metastatic prostate cancer reinforces the power of our Veracyte Diagnostics Platform. This platform helps harness our whole-transcriptome data-generation capabilities and our commitment to partnering with the research community to advance cancer understanding and innovation. Ultimately, our goal is to further help improve patient care,” added Phil Febbo, M.D., Veracyte’s Chief Scientific Officer and Chief Medical Officer.